null

Anti-Human IL 12/23 (Briakinumab) Dylight® 488 Biosimilar (IVMB0511)

SKU:
IVMB0511
Antibody Type:
Dylight Biosimilar
Applications:
IHC
FC
Drug Development
Pharmacokinetics
Disease Area:
Cancer
€749

Description

system_update_altDatasheetsystem_update_altMSDS
Product Name:Anti-Human IL 12/23 (Briakinumab) Dylight 488
SKU:IVMB0511
Size:100 µg
Antibody Type:Biosimilar Recombinant Human Monoclonal Antibody
Clone:ABT-874
Target:IL-12/IL-23 p40
Isotype:Human IgG1λ
Host Species:Human
Reactivity:Human
Applications:FA
Expression Host:HEK-293 Cells
FC Effector Activity:Active
Synonyms:IL-12p40; Interleukin 12; Interleukin 23; IL12; IL23; IL-12; IL-23
Product Concentration:0.2 mg/ml
Excitation Laser:Blue Laser (493 nm)
Immunogen:This antibody was produced by phage display technology.
Applications and Recommended Usage:FC The suggested concentration for Briakinumab biosimilar antibody for staining cells in flow cytometry is ≤ 1.0 μg per 106 cells in a volume of 100 μl. Titration of the reagent is recommended for optimal performance for each application.
Antigen Distribution:IL-12 is produced by dendritic cells, macrophages, neutrophils, and human B-lymphoblastoid cells. IL-23 is mainly secreted by activated dendritic cells, macrophages or monocytes.
Formulation:This DyLight 488 conjugate is formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.4, 1% BSA and 0.09% sodium azide as a preservative.
Specificity:This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Briakinumab. Briakinumab recognizes both human IL12 and IL23 via IL-12/23p40. This product is for research use only.
Additional Applications Reported In Literature:FA
Additional Reported Applications For Relevant Conjugates:BNWBELISAIP

Briakinumab is a human monoclonal antibody targets the p40 subunit shared by interleukins 12 and 23. IL-12 associates with IL-23α to form the heterodimeric cytokine IL-23. IL-23 is associated with various autoimmune inflammatory diseases, and is particularly highly expressed in psoriasis skin lesions. In addition, IL-23 is suspected to play a role in tumorigenesis. Briakinumab binds to and neutralizes human IL-12 and IL-23 (via their shared p40 subunit) and is being investigated for the treatment of rheumatoid arthritis, inflammatory bowel disease, and multiple sclerosis. Anti-Human IL 12/23 (Briakinumab) utilizes the same variable regions from the therapeutic antibody Briakinumab making it ideal for research projects.

Regulatory Status:Research Use Only (RUO). Non-Therapeutic.
Storage and Handling:This DyLight 488 conjugate is stable when stored at 2-8°C.Do not freeze.
Research Area:Biosimilars

Related Products